Success Stories: Within 21 Days NIW Case Approved for a Portuguese Fellow in Clinical Medicine with Diligent Case Preparation and PP Upgrade
Client’s Testimonial:
“Thank you so much for such great news!!”
On March 2nd, 2023, we received another EB-2 NIW (National Interest Waiver) approval for a Clinical Fellow in the Field of Clinical Medicine (Approval Notice).
General Field: Clinical Medicine
Position at the Time of Case Filing: Clinical Fellow
Country of Origin: Portugal
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: March 2nd, 2023
Processing Time: 21 days (Premium Processing Requested)
Case Summary:
A National Interest Waiver victory requires convincing the adjudicating bench of the merits of allowing a petitioner to continue his work in the U.S. Any applicant’s petition needs to contain a list of their academic and professional achievements along with a clear statement of purpose and letters of testimonial. So when an expert in clinical medicine came to us for his EB2-NIW (National Interest Waiver) approval, we made sure his petition was well-written. This meant including the following:
- His proposed endeavor was to work on optimizing the effectiveness of state-of-the-art imaging techniques to perform imaging-guided diagnostic and therapeutic procedures to provide accurate diagnoses for patients with lung and other thoracic malignancies.
- His research advancing his proposed endeavor is of great importance because it addresses major challenges related to the use of advanced clinical imaging methods for the diagnosis of various thoracic diseases, including lung cancer.
- His innovative research leads to effective, accurate, and efficient methods clinical researchers need for identifying, diagnosing, and monitoring lung cancer, among many other dangerous thoracic health conditions. As such, the continuation of his research is clearly of great benefit to clinicians around the world.
- Not only this, but his proposed endeavor also has broad implications for the United States. In particular, his specialized research provides the tools needed to more accurately and efficiently diagnose dangerous thoracic diseases, including cancer, in the United States.
- He has also been invited to conduct a peer review for an authoritative journal in his area of study. And his research has resulted in 12 peer-reviewed journal articles (4 of them first-authored) which have been cited a total of 155 times according to Google Scholar, thereby demonstrating that these publications are widely recognized and relied upon in the field of clinical medicine.
- We also found that he has relevant experience since he has pursued research directly related to his proposed endeavor for at least 13 years.
All of these factors helped us win the approval without an RFE and in just 21 days. We are glad to have been of aid to him in this case and we wish him all the best in his future endeavors.